Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
109 Cards in this Set
- Front
- Back
General properties of H1 blocking drugs
|
1. used in treatment of hayfever and urticaria, and a few IgE-mediated allergies.
2. toxicities reflect their effects on the ANS and CNS |
|
General properties of H2 blocking drugs
|
1. used in treatment of acid-peptic disease, especially heartburn and peptic ulcer
2. toxicities (almost exclusively cimetidine) include: a. inhibition of hepatic CYP450 b. antiandrogenic action |
|
Examples of typical H2 blockers
|
1. cimetidine
2. famotidine 3. nizatidine 4. ranitidine |
|
Examples of H3 blockers
|
1. clobenpropit
2. abt-239 (nootropic) 3. ciproxifan 4. ciprilisant |
|
In which cells is serotonin stored?
|
1. platelets
2. neurons 3. enterochromaffin cells 4. cells in the gut |
|
What is the main metabolite of serotonin?
|
1. hydroxyindoleacetic acid (HIAA)
2. is increased in urine of patients with carcinoid tumor |
|
Effects of increased serotonin (and other substances) produced by carcinoid tumor include
|
1. diarrhea
2. bronchospasm 3. variable changes in blood pressure 4. flushing of the skin |
|
Serotonin's effects are mediated by a large number of receptors, four of which are of clinical importance. Which ones?
|
1. 5-HT 1D (GPCR)
2. 5-HT2 (GPCR) 3. 5-HT3 (ion channel) 4. 5-HT4 (GPCR) |
|
Clinical value of serotonin?
|
Serotonin itself is of no value as a drug, but two more selective agonists are used:
1. 5-HT 1D (e.g., sumatriptan) for migraine. Toxicities include coronary vasospasm 2. 5-HT4 agonists (e.g., tegaserod and cisapride) increase the release of ACh in the gut--> increased motility. Toxicities include tosade de pointes arrhythmia and diarrhea. |
|
What is the standard treatment of migraine headache?
|
1. Simple analgesics, with sumatriptan or a similar "triptan" drug, or with ergotamine
2. Prophylaxis is partially successful using propranolol, amitriptyline, calcium channel blockers, and others |
|
H1 receptor functions:
|
1. Gq coupled
2. increased IP3 and DAG, smooth muscle contraction (EXCEPT vessels), increased secretion 3. located in smooth muscle, gland cells, some nerve endings |
|
H2 receptor functions:
|
1. Gs coupled
2. Increased cAMP, increased acid secretion, cardiac stimulation 3. located in parietal cells (stomach) and heart |
|
H3 receptor functions
|
1. Gi coupled
2. decreased cAMP, modulates transmitter release 3. presynaptic autoreceptor in nerve endings |
|
Histamine H1 antagonists can be divided into three groups. What are they? And what are their uses?
|
1. First generation, older - allergy, sleep aid, motion sickness, nausea of chemotherapy
2. First generation, newer - allergy 3. Second generation - allergy |
|
Examples of first generation, older, H1 antagonists
|
1. Diphenhydramine
2. dimenhydrinate |
|
Examples of first generation, newer, H1 antagonists
|
1. chlorpheniramine
2. cyclizine |
|
Examples of second generation H1 antagonists
|
1. fexofenadine
2. loratadine 3. desloratadine 4. cetrizine |
|
Toxicities of first generation, older antihistamines
|
1. strong alpha and muscarinic block
2. strongly sedative |
|
Toxicities of first generation, newer antihistamines
|
1. much reduced sedative and ANS effects
|
|
Toxicities of second generation antihistamines
|
negligible CNS and ANS effects
|
|
Location and function of 5-HT1D receptors
|
1. Located in neurons, perhaps other places
2. mediates increased IP3, DAG |
|
Location and function of 5-HT2 receptors
|
1. smooth muscle, other?
2. increased IP3 and DAG, smooth muscle contraction |
|
Location and function of 5-HT3 receptors
|
1. chemoreceptors in the central and peripheral nervous system
2. nasuea and vomiting |
|
Location and function of 5-HT4 receptors
|
1. neurons in the gut
2. increased GI motility |
|
Some notes on 5-HT2 antagonists
|
5-HT2 antagonists, such as ketanserin, have been developed for the treatment of carcinoid tumors. However, older drugs with overlapping effects (e.g., phenoxybenzamine [5-HT+alpha blocker] or cyproheptadine [5-HT+H1 blocker]) appear to be just as useful. In addition ketanserin has been used to treat HTN in Europe.
|
|
Indications for 5-HT3 antagonists?
|
Extremely useful antinauseants and antiemetics for patients undergoing general anesthesia or chemotherapy
|
|
Examples of 5-HT3 antagonists
|
1. ondansetron
2. granisetron 3. tropisetron 4. dolasetron |
|
Other serotonin related drugs
|
1. ergot alkaloids (complex partial agonists at 5-Ht, alpha, and dopamine receptors)
2. ergotamine (for migraine) - natural 3. ergonovine (oxytocic agent) - natural 4. bromocriptine (used in hyperprolactinemia and parkinsonism) - semisynthetic 5. pergolide (parkinsonism) - semisynthetic 6. LSD - semisynthetic. no meidcal use, powerful hallucinogenic |
|
Effects and clinical uses of endogenous PGE2
|
1. vasodilation, bronchodilation, oxytocic
2. oxytocic (as dinoprostone) |
|
Effects and clinical uses of PGE1 analog misoprostol
|
1. increased bicarbonate and mucus secretion in stomach
2. prevention of NSAID-induced ulcers |
|
Effects and clinical uses of PGE1 analog alprostadil
|
1. smooth muscle relaxation
2. erectile dysfunction |
|
Effects and clinical uses of endogenous PGF2alpha
|
1. vasoconstriction, bronchoconstriction, oxytocic
2. no clinical uses |
|
Effects and clinical uses of PGF2alpha analog latanoprost
|
1. increased aqueous humor drainage
2. chronic glaucoma |
|
Effects and clinical uses of prostacyclin (PGI2)
|
1. prevents platelet aggregation, vasodilation
2. severe pulmonary hypertension (as epoprostenol) |
|
Effects and clinical uses of thromboxane (TXA2)
|
1. facilitates platelet aggregation
2. no clinical uses |
|
Effects and clinical uses of LTB4
|
1. leukocyte chemotaxis
2. no clinical uses |
|
Effects and clinical uses of LTC4
|
1. bronchoconstriction
2. no clinical uses |
|
Effects and clinical uses of LTD4
|
1. bronchoconstriction
2. no clinical uses |
|
Difference between NSAIDs and steroids?
|
Steroids are powerful anti-inflammatory agents, whereas NSAIDs have weaker anti-inflammatory actions, but are more suitable for long-term therapy because they are less toxic
|
|
Older NSAIDs include
|
1. aspirin
2. salicylate |
|
Newer non-COX selective NSAIDs include
|
1. indomethacin
2. ibuprofen 3. diclofenac 4. indomethacin 5. ketorolac 6. naproxen 7. piroxicam |
|
Selective COX-2 inhibitors include
|
1. celecoxib
2. valdecoxib 3. other members of this drug |
|
Half-life and comments on aspirin
|
1. 15 minutes (but active metabolite has a half life of 3-15 hours)
2. Widely used for pain, fever, inflammation, and antiplatelet action |
|
Half-life and comments on celecoxib
|
1. 11 hours
2. selective COX-2 inhibitor; a sulfonamide |
|
Half-life and comments on diclofenac
|
1. 1.1 hours
2. general use in inflammation, pain |
|
Half-life and comments on ibuprofen
|
1. 2 hours
2. general use in inflammation, pain |
|
Half-life and comments on indomethacin
|
1. 4-5 hours
2. general use in inflammation, pain |
|
Half-life and comments on ketorolac
|
1. 4-10 hours
2. parenteral use in pain; an opioid substitute |
|
Half-life and comments on naproxen
|
1. 12 hours
2. longer action |
|
Half-life and comments on piroxicam
|
1. 20 hours
2. longest action |
|
Half-life and comments on salicylic acid
|
1. 3-15 hours
2. active metabolite of aspirin, zero order elimination at high concentrations |
|
What sets aspirin apart from all other NSAIDs?
|
It irreversibly blocks COX, especially in platelets. Its antiplatelet effect is, therefore, longer in duration (24-48 hrs) than its anti-inflammatory and analgesic action (4-6 hours)
|
|
Toxicities of the NSAIDs include
|
1. GI upset
2. peptic ulcers with or without bleeding 3. renal damage 4. diversion of arachidonic acid metabolism to the leukotriene pathway (may rarely present with anaphylaxis) |
|
Pros and cons of COX-2 selective inhibitors
|
1. Pro: lower risk of GI bleeding
2. Con. increased risk of cardiovascular events (stroke and MI) |
|
Comments on acetaminophen
|
1. similar analgesic and antiypritic effect to aspirin
2. weak COX inhibitor 3. little or no anti-inflammatory effect 4. metabolites of acetaminophen may cause hepatic necrosis (overdose) |
|
What is gout?
|
1. chronic metabolic disease characterized by an elevated body load of uric acid.
2. manifested by depositus of urate crystals in soft tissue and joints 3. in the joints, these crystals trigger episodes of acute painful arthritis |
|
Which classes of drugs are used in the treatment of gout?
|
1. anti-inflammatory agents (mainstay of therapy)
2. uricosuric agents (increases excretion of uric acid) 2. inhibitor of uric acid synthesis (allopurinol) |
|
Which anti-inflammatory drugs are are often used in the treatment of acute joint pain?
|
1. ibuprofen and indomethacin
2. colcichine (highly selective for gouty arthritis) - but is usually restricted to low-dose prophylactic therapy because of GI and hepatic toxicity |
|
Which uricosuric agents are normally used in the treatment of gout?
|
1. probenecid
2. sulfinpyrazone They inhibit the uric acid reabsorption transporter in the straight segment of proximal tubules |
|
Mechanism of action of allopurinol
|
1. inhibits xanthine oxidase
2. reduces concentration of insoluble uric acid 3. increases concentration of uric acid precursors, xanthine and hypoxanthine |
|
Clinical correlations on the treatment of gout
|
1. acute attacks require strong anti-inflammatory drugs, strong analgesics, or both
2. indomethacin and ketorolac are often used. ketorolac may be used parenterally 3. uricosurics may precipitate an immediate attack and should always be used in conjunction with colcichine or other agents initially 4. allopurinol's benefits are slow in onset and are suitable only for long-term therapy |
|
In addition to the obvious cardiovascular events that hypertriglyceridemia may cause, it may also contribute to an incresed risk of
|
acute pancreatitis
|
|
Drugs used in hypercholesterolemia include
|
1. statins
2. resins 3. ezetimibe 4. niacin 5. fibrates |
|
Mechanism of action of statins
|
(e.g., levostatin and atorvastatin)
1. inhibitors of cholesterol synthesis (HMG-CoA reductase inhbitors) 2. reduced cholesterol concentrtion results in increased LDL-binding receptors on liver cells, which increases clearance of LDL from blood 3. most statins only reduce cholesterol, but atorvastatin reduces both cholesterol and triglyceride levels |
|
Mechanism of action of resins
|
(e.g., cholestyramine and colestipol)
1. nonabsorbable macromolecules, bind to and prevent reabsorption of cholesterol and bile acids 2. resins tend to increase triglycerides |
|
Mechanism of action of exetimibe
|
new drug that reduces the absorption of cholesterol from the intestines, the exact mechanism is unknown
|
|
Mechanism of action of niacin
|
(nicotinic acid and vitamin b3)
1. the exact mechanism is not fully understood. 2. high doses cause a decrease in secretion of VLDL from the liver into blood, and thus decreased LDL. 3. is also effective in hypertriglyceridemia and may cause increase in HDL |
|
Mechanism of action of the fibrates
|
(e.g., gemfibrozil and fenofibrate)
1. activate peroxisome proliferator-activator receptor alpha (PPAR-a) 2. increases synthesis of lipoprotein lipase and other enzymes 3. serum triglyceride concentrations are reduced, may be a reduction in LDL |
|
Toxicities of statins
|
1. may cause serious skeletal muscle or liver damage
2. may interfere with myelination in growing infants. These drugs are contraindicated in pregnancy |
|
Toxicities of niacin
|
1. high doses causes a transient uncomfortable flushing with itching (may be reduced with aspirin)
2. may rarely cause elevation of: a. liver enzymes b. hyperuricemia c. glucose intolerance |
|
Toxicities of resins
|
1. unpleasant gritty taste
2. may cause GI discomfort (including bloating and constipation) 3. impaired fat-soluble vitamin and drug absorption Should be avoided in hypertriglyceridemia |
|
Toxicities of fibrates
|
1. nausea
2. skin rash 3. increased effect of antiplatelet drugs 4. increased risk of gall stones |
|
Anticoagulants include
|
1. warfarin (oral; blocks reactivation of vitamin K epoxide; monitor with PT and INR)
2. heparin (parenterally, binds factor Xa and AT III) |
|
Heparin is available in both HMW and LMW forms. The differences
|
1. HMW - binds Xa and AT III. AT III in this bound form is activated 1000-fold --> immediate clotting inhibition. The response is variable, must monitor.
b. LMW - inhibit factor Xa, but less effect on AT III. Response is predictable and so does not require monitoring. |
|
Examples of LMW heparins
|
1. enoxaparin
2. dalteparin |
|
Major clinical application of heparins and warfarin are
|
in the prevention and treatment of venous clotting, especially DVT
|
|
Toxicities of heparins and warfarin
|
1. bleeding
2. warfarin is a teratogen 3. heparin causes dose-dependent thrombocytopenia, but occasionally causes a more severe loss of platelets |
|
Most important antiplatelet drugs include
|
1. aspirin
2. clopidogrel - blocks ADP receptor on platelets 3. ticlopidine - blocks ADP receptor on platelets 4. fiban drugs (eptifibatide and tirofiban) - IIb/IIIa blocker 5. abciximab - IIb/IIIa blocker |
|
Most important clinical use of fibrinolytics
|
intravenous administration for pulmonary embolism and myocardial infarction
|
|
Most important fibrinolytic drugs
|
1. streptokinase - may cause allergic response, bleeding
2. alteplase (tPA), reteplase - bleeding 3. urokinase - bleeding |
|
Anemia results from
|
1. inadequate dietary iron
2. inadequate vitamin intake 3. inadequate RBC production 4. accelerated RBC breakdown |
|
What is anemia?
|
a deficiency of red blood cells (RBCs) or hemoglobin
|
|
For simple iron deficiency anemia, oral supplementation is effective. In what form is iron given?
|
1. ferrous sulfate
2. ferrous gluconate ferric iron salts are poorly absorbed |
|
Iron is irritating to the stomach, annd some patients cannot tolerate the doses required for rapid correction of severe deficiency. What options do these patients have?
|
1. iron dextran
2. iron sucrose complex 3. iron gluconate complex all parenteral iron |
|
Manifestations of iron poisoning include
|
1. vomiting
2. abdominal pain 3. diarrhea 3. necrotizing enteritis, followed by shock, lethargy, metabolic acidosis, death |
|
How do you treat iron poisoning?
|
Prompt diagnosis and an iron chelator, such as deferoxamine
|
|
Growth factor used for anemia
|
1. epoetin (human recombinant erythropoietin)
2. increases RBC production 3. may cause HTN, thrombotic events |
|
Growth factor used for granulocytopenia (F)
|
1. filgrastim (human recombinant GM-CSF)
2. increases neutrophil production 3. may cause bone pain |
|
Growth factor used for granulocytopenia (S)
|
1. sargramostim (human recombinant G-CSF)
2. stimulates most marrow precursors, but increases neutrophil production the most 3. may cause fever, myalgia, peripheral and pulmonary edema |
|
Growth factors used for thrombocytopenia
|
1. oprelvekin (human recombinant IL-11)
2. stimulates platelet production 3. may cause fatigue, headache, dizziness |
|
Definition of asthma
|
asthma is a chronic inflammtory airway disease, with superimposed transient episodes of bronchoconstriction
|
|
Therapy of asthma consists of
|
1. bronchodilators - control of symptoms
2. anti-inflammatory drugs - prophylaxis |
|
Bronchoconstriction in asthma is mediated mostly by
|
1. leukotrienes
2. other smooth muscle activators from mast cells and eosinophils in the airways |
|
Bronchodilators consist of
|
1. beta2-selective agonists
2. muscarinic blockers 3. theophylline |
|
Drug of choice in acute episodes of asthmatic bronchoconstriction
|
1. beta2-selective agonists, such as:
a. albuterol b. metaproterenol 2. they are physiologic leukotriene antagonists (and others increasing cAMP) 3. |
|
Toxicities of beta2-selective agonists
|
1. tremor
2. tachycardia However, do not limit the drug during an acute attack: uncontrolled bronchoconstriction can be fatal |
|
The most important muscarinic antagonists used in asthma are atropinelike. Their names are
|
1. ipratropium
2. tiotropium *not as effective as SABAs |
|
Toxicities of ipratropium and tiotropium
|
1. dry mouth
2. tachycardia (rarely) 3. cycloplegia (rarely) |
|
Toxicities of theophylline include
|
1. GI disturbances
2. tremor 3. arrhythmias 4. convulsions |
|
Third kind of bronchodilator
|
1. theophylline - is related to caffeine and theobromine, but more effective than either
2. inhibits phosphodiesterase -->increased levels of cAMP 3. not active when inhaled |
|
Which anti-inflammatory drugs are used in asthma?
|
1. corticosteroids
2. mast cell stabilizers 3. leukotriene antagonists |
|
Most important prophylactic agent for asthma
|
corticosteroids - given by metered-dose inhaler when possible
|
|
Which steroids are most commonly used in asthma?
|
1. beclomethasone
2. fluticasone 3. uhm... others... |
|
How do corticosteroids help in asthma?
|
inhibit leukotriene and inflammatory cytokine production and release
|
|
Toxicities of inhaled corticosteroids include
|
1. temporary retardation of growth young children
2. candidal yeast infection of larynx |
|
Mast cell stabilizers used in asthma include
|
1. cromolyn
2. nedocromil highly insoluble compounds that can be administered by metered-dose inhalation with practically no systemic toxicity |
|
How do mast cell stabilizers work?
|
Probably by inhibiting mast cell release of inflammatory and allergic mediators, including leukotrienes, cytokines, and histamine
|
|
Leukotriene receptor antagonists used in asthma
|
1. zafirlukast
2. montelukast orally active (advantageous in young children and others who can't use inhalers) |
|
Downside of leukotriene receptor antagonists?
|
1. not as effective as corticosteroids
2. no value in acute bronchospasm |